Teacher Retirement System of Texas Sells 11,886 Shares of Moderna, Inc. (NASDAQ:MRNA)

Teacher Retirement System of Texas reduced its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 11.7% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 89,496 shares of the company's stock after selling 11,886 shares during the quarter. Teacher Retirement System of Texas' holdings in Moderna were worth $2,537,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Itau Unibanco Holding S.A. increased its holdings in Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after purchasing an additional 343 shares in the last quarter. Commonwealth Equity Services LLC increased its holdings in Moderna by 0.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock worth $3,099,000 after purchasing an additional 345 shares in the last quarter. Larson Financial Group LLC increased its holdings in Moderna by 39.1% in the fourth quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock worth $53,000 after purchasing an additional 356 shares in the last quarter. Deseret Mutual Benefit Administrators increased its holdings in Moderna by 53.3% in the first quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock worth $32,000 after purchasing an additional 392 shares in the last quarter. Finally, Parallel Advisors LLC increased its holdings in Moderna by 11.4% in the first quarter. Parallel Advisors LLC now owns 4,403 shares of the company's stock worth $125,000 after purchasing an additional 451 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Evercore ISI decreased their price objective on Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a report on Friday, May 2nd. Royal Bank Of Canada decreased their price objective on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. William Blair restated a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. JPMorgan Chase & Co. decreased their price objective on Moderna from $33.00 to $26.00 and set an "underweight" rating for the company in a report on Thursday, May 22nd. Finally, Citigroup assumed coverage on Moderna in a report on Thursday, March 13th. They set a "neutral" rating and a $40.00 price objective for the company. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Moderna has an average rating of "Hold" and an average price target of $46.61.

Moderna Stock Performance

NASDAQ MRNA traded down $0.70 during trading hours on Friday, hitting $33.58. The company had a trading volume of 3,855,639 shares, compared to its average volume of 8,828,100. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $129.39. The firm has a 50 day simple moving average of $27.09 and a 200 day simple moving average of $31.26. The firm has a market capitalization of $12.99 billion, a price-to-earnings ratio of -3.85 and a beta of 1.84.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. The firm had revenue of $108.00 million during the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. The company's revenue for the quarter was down 35.3% on a year-over-year basis. During the same quarter last year, the company posted ($3.07) EPS. On average, research analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.